Polydopamine / copolymer composite microsphere as well as preparation method and application thereof
Through the design of polydopamine/copolymer composite microspheres, the use of racemic polylactic acid-glycolic acid copolymer to coat drug particles and modify polydopamine, the problems of restricted drug delivery and poor biocompatibility in the treatment of inner ear disease are solved. Efficient and safe targeted drug delivery and uniform drug release are achieved.
Patent Information
- Application Number
- CN202310572275.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-22
AI Technical Summary
Existing treatment methods for inner ear diseases. The blood-laundering barrier in the cochlear blood lines limits drug delivery, resulting in low bioavailability and systemic administration brings toxic side effects. The round window drug delivery device is prone to infect and secondary surgery risks. , DNA vectors have poor biocompatibility and low drug loading.
Develop polydopamine/copolymer composite microspheres to coat drug particles through racemic polylactic acid-glycolic acid copolymer and modify polydopamine on the surface of the coating to form targeted point administration, ensuring that the microspheres are on the circular window niche Adhesion and degradation to avoid infection and secondary surgery risks while improving biocompatibility and drug loading.
Targeted targeted drug delivery is achieved, which improves the bioavailability of inner ear drugs, reduces toxic side effects, avoids the risks of infection and secondary surgery, and reduces the problem of uneven drug delivery concentration by uniformly releasing drugs.
Smart Images

Figure CN118987260A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to a polydopamine / copolymer composite microsphere and a preparation method and application thereof. Background Art
[0002] Inner ear diseases caused by sensorineural hearing loss, tinnitus and vestibular diseases seriously affect the physical and mental health of patients. With the development of modern society, factors such as life pressure, aging population and industrial noise have led to an increasing incidence of inner ear diseases. In view of the large number of inner ear diseases, oral medications, intravenous or arterial injections and other systemic administration methods are currently commonly used in clinical treatment. However, the presence of the blood-labyrinth barrier (BLB) in the stria vascularis of the cochlea limits the delivery of drugs to the inner ear tissue.
[0003] In order to overcome the problems of low bioavailability and strong systemic toxicity caused by systemic drug administration, round window drug administration for the treatment of inner ear diseases has come into people's attention in recent years. The mechanism of round window drug administration is to directly pass the drug through the round window niche into the inner ear. Due to the continuous circulation of lymph in the inner ear, the drug is diffused and distributed throughout the cochlea.
[0004] For example, there is a method to provide an inner ear drug delivery device, whose drug delivery component contains a drug eluting polymer material containing therapeutic drugs, which can be released into the patient's inner ear in an effective amount over time to treat inner ear diseases; there is also a method to provide a continuous inner ear drug delivery device, which can achieve continuous drug delivery in the inner ear by wearing the device. However, both drug delivery devices are prone to infection when worn, and face the problem of secondary damage to the ear when the device is removed after the treatment is completed.
[0005] Another method provides a vector composed of four self-assembled DNA single strands for the treatment of inner ear diseases. However, DNA nucleic acid molecules are toxic, resulting in poor biocompatibility of this vector. At the same time, this vector has a tetrahedral structure, and the drug loading capacity will be lower than that of a spherical structure. Summary of the invention
[0006] Based on this, the present application provides a polydopamine / copolymer composite microsphere and its preparation method and application. The polydopamine / copolymer composite microsphere can be attached to the round window niche to achieve the purpose of targeted drug delivery, and can be fully degraded to avoid secondary damage to the ear, and has good biocompatibility and high drug loading.
[0007] In a first aspect of the present application, a polydopamine / copolymer composite microsphere is provided, comprising:
[0008] Drug particles, a coating layer coated on the surface of the drug particles, and polydopamine grafted on the surface of the coating layer;
[0009] The coating layer is composed of racemic polylactic acid-glycolic acid copolymer.
[0010] In one embodiment, the surface of the coating layer is modified with carboxyl groups, and the polydopamine is grafted to the coating layer via the carboxyl groups.
[0011] In one embodiment, the racemic poly(lactic acid-co-glycolic acid) has one or both of the following characteristics (1) to (2):
[0012] (1) The intrinsic viscosity of the racemic poly(lactic acid-co-glycolic acid) copolymer is 0.16 dL / g to 1.2 dL / g;
[0013] (2) The molar percentage of polylactic acid to glycolic acid in the racemic polylactic acid-glycolic acid copolymer is (80% to 50%): (20% to 50%).
[0014] In one embodiment, the mass ratio of the racemic poly(lactic acid-glycolic acid) copolymer to the drug particles is (50-100):1.
[0015] In one embodiment, the mass ratio of the racemic poly(lactic acid-glycolic acid) copolymer to the polydopamine is (100-150):1.
[0016] In one embodiment, the drug particles include drugs for treating inner ear diseases;
[0017] Optionally, the drug for treating inner ear diseases includes one or more of hydrocortisone, cortisone, prednisone, methylprednisolone, prednisolone, dexamethasone, betamethasone and mometasone furoate.
[0018] The second aspect of the present application provides a method for preparing polydopamine / copolymer composite microspheres, comprising the following steps:
[0019] preparing respectively an aqueous dispersion of the drug and an organic solvent dispersion of a racemic polylactic acid-glycolic acid copolymer;
[0020] Adding the aqueous dispersion of the drug to the stirred organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer, centrifuging and drying to prepare drug particles with a coating layer on the surface;
[0021] Polydopamine is grafted on the surface of the coating layer.
[0022] In one embodiment, grafting polydopamine on the surface of the coating layer comprises the following steps:
[0023] The surface of the coating layer is modified with carboxyl groups, and polydopamine is grafted onto the carboxyl groups.
[0024] In one embodiment, modifying the surface of the coating layer with carboxyl groups comprises the following steps:
[0025] Etching the surface of the coating layer to form the carboxyl group;
[0026] Optionally, the etching treatment includes one or more of alkali treatment, acid treatment and plasma treatment;
[0027] Further optionally, the etching treatment is an alkali treatment, and the alkali used in the alkali treatment includes one or more of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate.
[0028] In one embodiment, grafting polydopamine to the carboxyl group comprises the following steps:
[0029] The drug particles after the surface of the coating layer is modified with carboxyl groups are mixed with a dopamine dispersion to graft the dopamine to the carboxyl groups and introduce oxygen to cause the dopamine to undergo oxidative self-polymerization to form the polydopamine;
[0030] Optionally, the mass concentration of dopamine in the dopamine dispersion is 0.2% to 5%;
[0031] Optionally, the pH of the dopamine dispersion is 5.8 to 8.6;
[0032] Optionally, the oxygen is introduced for 30 min to 200 min.
[0033] In one embodiment, the aqueous dispersion of the drug is added to the stirred organic solvent dispersion of the racemic poly(lactic-co-glycolic acid) copolymer, and the steps of centrifugation and drying have one or more of the following characteristics (1) to (5):
[0034] (1) The stirring rate is 1000 rpm to 2000 rpm;
[0035] (2) The stirring time is 5h to 7h;
[0036] (3) The rate of addition of the aqueous dispersion of the drug is 3 to 7 mL / min;
[0037] (4) The centrifugal speed is 5000 rpm to 9000 rpm;
[0038] (5) The drying method is freeze drying; optionally, the freeze drying temperature is -60°C to -80°C, and the freeze drying time is 6h to 10h.
[0039] In one embodiment, the mass concentration of the drug in the aqueous dispersion of the drug is 0.1% to 5%.
[0040] In one embodiment, the organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer has one or both of the following characteristics (1) to (2):
[0041] (1) The mass concentration of the racemic polylactic acid-glycolic acid copolymer in the organic solvent dispersion of the racemic polylactic acid-glycolic acid copolymer is 5% to 20%;
[0042] (2) The organic solvent includes one or more of acetone, dichloromethane, chloroform, trifluoroacetic acid and hexafluoroisopropanol.
[0043] In one embodiment, after the step of grafting polydopamine on the surface of the coating layer is completed, the step of washing and drying is also included;
[0044] Optionally, the cleaning method is water washing;
[0045] Optionally, the drying method is freeze drying;
[0046] Further optionally, the freeze-drying temperature is -60°C to -80°C, and the freeze-drying time is 6h to 10h.
[0047] The third aspect of the present application provides an inner ear drug delivery preparation, comprising the polydopamine / copolymer composite microspheres described in the first aspect or the polydopamine / copolymer composite microspheres prepared by the preparation method described in the second aspect.
[0048] The fourth aspect of the present application provides the use of the polydopamine / copolymer composite microspheres described in the first aspect or the polydopamine / copolymer composite microspheres prepared by the preparation method described in the second aspect in the preparation of drugs for treating inner ear diseases.
[0049] The above-mentioned polydopamine / copolymer composite microspheres, by coating the drug particles with racemic polylactic acid-glycolic acid copolymer, and modifying polydopamine on the coating layer, can effectively adhere to the round window niche, achieve the purpose of targeted fixed-point drug delivery, and solve the problems of low bioavailability and strong systemic toxic and side effects of systemic drug delivery. At the same time, the composite microspheres have good biocompatibility, the sphere has a high drug loading, and can be completely degraded after the treatment is completed. The degradation products can flow out of the inner ear through the Eustachian tube, converted into water and carbon dioxide, and thus be metabolized by the human body, without the need for secondary surgery to remove, avoiding the risks brought by secondary surgery, and will not cause diseases such as infection due to wearing a drug delivery catheter. In addition, the use of racemic polylactic acid-glycolic acid copolymers can also match the degradation time of the composite microspheres with the treatment cycle of the inner ear.
[0050] Furthermore, the polydopamine / copolymer composite microspheres are relatively small in size, which improves the stability of adhesion to the round window niche, is not easy to fall off, and is convenient for drug administration. In addition, the drug can be released continuously and evenly, reducing the problem of sudden release or inability to release continuously, thereby reducing the problem of uneven drug concentration. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 Schematic diagram of the structure of polydopamine / copolymer composite microspheres provided for some examples of this application;
[0052] Figure 2 This is the infrared spectrum of the polydopamine / copolymer composite microspheres prepared in Example 1 of the present application;
[0053] Figure 3 This is a scanning electron microscope image of the polydopamine / copolymer composite microspheres prepared in Example 1 of the present application. DETAILED DESCRIPTION
[0054] The following is a further detailed description of the polydopamine / copolymer composite microspheres and their preparation methods and applications of the present application in conjunction with specific examples. The present application can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present application more thoroughly understood.
[0055] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0056] As used herein, "one or more" refers to any one, any two, or any two or more of the listed items.
[0057] In this application, "first aspect", "second aspect", "third aspect", "fourth aspect", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.
[0058] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0059] In this application, when it comes to numerical ranges, unless otherwise specified, the above numerical ranges are deemed to be continuous and include the minimum and maximum values of the range, as well as each value between such minimum and maximum values. Further, when a range refers to an integer, each integer between the minimum and maximum values of the range is included. In addition, when multiple ranges are provided to describe features or characteristics, the ranges can be merged. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges included therein.
[0060] The percentage contents involved in this application, unless otherwise specified, refer to mass percentage for solid-liquid mixing and solid-solid mixing, and refer to volume percentage for liquid-liquid mixing.
[0061] The percentage concentrations mentioned in this application, unless otherwise specified, refer to the final concentration, which refers to the percentage of the added component in the system after the addition of the component.
[0062] The temperature parameters in this application, unless otherwise specified, allow for both constant temperature treatment and treatment within a certain temperature range. The constant temperature treatment allows the temperature to fluctuate within the accuracy range of instrument control.
[0063] The room temperature in the present application generally refers to 4°C to 30°C, preferably 20±5°C.
[0064] Some examples of the present application provide a polydopamine / copolymer composite microsphere, the structure of which is as follows: Figure 1 As shown, including:
[0065] Drug particles 100, a coating layer 200 coated on the surface of the drug particles, and polydopamine 300 grafted on the surface of the coating layer 200;
[0066] The composition of the coating layer 200 includes racemic poly(lactic-co-glycolic acid).
[0067] In some of the examples, the surface of the coating layer is modified with carboxyl groups, and the polydopamine is grafted to the coating layer via the carboxyl groups.
[0068] In some of the examples, the intrinsic viscosity of the racemic polylactic acid-glycolic acid copolymer is 0.16dL / g to 1.2dL / g. The test conditions for the intrinsic viscosity here are: sample concentration is 0.1g / dl, chloroform is the solvent, and the test is performed at 25°C. Specifically, the intrinsic viscosity of the racemic polylactic acid-glycolic acid copolymer includes but is not limited to: 0.16dL / g, 0.24dL / g, 0.4dL / g, 0.6dL / g, 0.8dL / g, 1.2dL / g, 0.16-0.24dL / g, 0.4-0.6dL / g, 0.8-1.2dL / g. Further, the intrinsic viscosity of the racemic polylactic acid-glycolic acid copolymer is 0.4-0.6dL / g.
[0069] In some examples, the molar percentage of polylactic acid to glycolic acid in the racemic polylactic acid-glycolic acid copolymer is (80% to 50%): (20% to 50%). Specifically, the molar percentage of polylactic acid to glycolic acid includes but is not limited to: 80:20, 70:30, 65:35, 60:40, 55:45, 50:50. Further, the molar percentage of polylactic acid to glycolic acid is (65% to 55%): (35% to 45%).
[0070] In some examples, the mass ratio of the racemic poly(lactic acid-co-glycolic acid) to the drug particles is (50-100): 1. Specifically, the mass ratio includes but is not limited to: 50: 1, 60: 1, 70: 1, 80: 1, 90: 1, 100: 1.
[0071] In some examples, the mass ratio of the racemic poly(lactic acid-co-glycolic acid) to the polydopamine is (100-150): 1. Specifically, the mass ratio includes but is not limited to: 100: 1, 110: 1, 120: 1, 130: 1, 140: 1, 150: 1.
[0072] In some examples, the drug particles include drugs for treating inner ear diseases. Without limitation, the drugs for treating inner ear diseases include one or more of hydrocortisone, cortisone, prednisone, methylprednisolone, prednisolone, dexamethasone, betamethasone and mometasone furoate.
[0073] In some other examples of the present application, a method for preparing polydopamine / copolymer composite microspheres is provided, comprising the following steps:
[0074] S1: preparing an aqueous dispersion of the drug and an organic solvent dispersion of a racemic poly(lactic-co-glycolic acid) copolymer respectively;
[0075] S2: adding the aqueous dispersion of the drug to the stirred organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer, centrifuging and drying to prepare drug particles with a coating layer on the surface;
[0076] S3: Grafting polydopamine on the surface of the coating layer.
[0077] It can be understood that the technical scheme of the drug, racemic polylactic acid-co-glycolic acid copolymer and polydopamine is the same as the above-mentioned polydopamine / copolymer composite microspheres, and has similar advantages, which will not be repeated here.
[0078] Further, in step S1:
[0079] In some examples, the mass concentration of the drug in the aqueous dispersion of the drug is 0.1% to 5%. Specifically, the mass concentration of the drug in the aqueous dispersion of the drug includes but is not limited to: 0.1%, 1%, 1.5%, 2%, 2.5%, 5%.
[0080] In some examples, the method for preparing the aqueous dispersion of the drug includes mixing the drug with water. Without limitation, the mixing method is stirring, the stirring rate is 200rpm to 600rpm, and the stirring time is 2h to 8h. Specifically, the stirring rate includes but is not limited to: 200rpm, 300rpm, 400rpm, 450rpm, 500rpm, 550rpm, 600rpm; the stirring time includes but is not limited to: 2h, 3h, 4h, 5h, 6h, 7h, 8h.
[0081] In some of the examples, the mass concentration of the racemic polylactic acid-glycolic acid copolymer in the organic solvent dispersion of the racemic polylactic acid-glycolic acid copolymer is 5% to 20%. Specifically, the mass concentration of the racemic polylactic acid-glycolic acid copolymer in the organic solvent dispersion of the racemic polylactic acid-glycolic acid copolymer includes but is not limited to: 5%, 8%, 10%, 12%, 14%, 15%, 17%, 20%.
[0082] In some examples, the organic solvent includes one or more of acetone, dichloromethane, chloroform, trifluoroacetic acid, and hexafluoroisopropanol.
[0083] In some examples, the method for preparing the organic solvent dispersion of the racemic polylactic acid-glycolic acid copolymer includes mixing the racemic polylactic acid-glycolic acid copolymer with an organic solvent. Without limitation, the mixing method is stirring, the stirring rate is 400rpm to 1000rpm, and the stirring time is 2h to 6h. Specifically, the stirring rate includes but is not limited to: 400rpm, 500rpm, 600rpm, 650rpm, 700rpm, 750rpm, 800rpm, 900rpm, 1000rpm; the stirring time includes but is not limited to: 2h, 3h, 4h, 4.5h, 5h, 6h, 7h, 8h.
[0084] Further, in step S2:
[0085] In some examples, the stirring rate is 1000 rpm to 2000 rpm. Specifically, the stirring rate includes but is not limited to: 1000 rpm, 1100 rpm, 1200 rpm, 1300 rpm, 1400 rpm, 1500 rpm, 1600 rpm, 1700 rpm, 1800 rpm, 1900 rpm, 2000 rpm.
[0086] In some examples, the stirring time is 5 hours to 7 hours. Specifically, the stirring time includes but is not limited to: 5 hours, 5.5 hours, 6 hours, 6.5 hours, and 7 hours.
[0087] In some examples, the rate of addition of the aqueous dispersion of the drug is 3 to 7 mL / min. Specifically, the rate of addition of the aqueous dispersion of the drug includes but is not limited to: 3 mL / min, 4 mL / min, 4.5 mL / min, 5 mL / min, 5.5 mL / min, 6 mL / min, 7 mL / min. Further, the rate of addition of the aqueous dispersion of the drug is 4 to 6 mL / min.
[0088] In some examples, the centrifugal rotation speed is 5000 rpm to 9000 rpm. Specifically, the centrifugal rotation speed includes but is not limited to: 5000 rpm, 6000 rpm, 7000 rpm, 8000 rpm, 9000 rpm.
[0089] In some of the examples, the drying method is freeze drying. Furthermore, the freeze drying temperature is -60°C to -80°C, and the freeze drying time is 6h to 10h. Specifically, the freeze drying temperature includes but is not limited to: -60°C, -65°C, -70°C, -75°C, -80°C; the freeze drying time includes but is not limited to: 6h, 7h, 7.5h, 8h, 9h, 10h.
[0090] Furthermore, in step S3, grafting polydopamine on the surface of the coating layer comprises the following steps:
[0091] S31: modifying the surface of the coating layer with carboxyl groups;
[0092] S32: Grafting polydopamine onto the carboxyl group.
[0093] Furthermore, in step S31, modifying the surface of the coating layer with carboxyl groups comprises the following steps:
[0094] The surface of the coating layer is etched to form the carboxyl group.
[0095] Without limitation, the etching treatment includes one or more of alkali treatment, acid treatment and plasma treatment. The plasma treatment may be glow discharge plasma treatment, for example. Further, the etching treatment is alkali treatment.
[0096] In some examples, the alkali used in the alkali treatment includes one or more of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate. Without limitation, the alkali treatment is carried out using an aqueous solution of the alkali, the mass concentration of the aqueous solution of the alkali is 0.1 g / L to 0.5 g / L, and the alkali treatment time is 20 min to 180 min.
[0097] Furthermore, in step S32, grafting polydopamine to the carboxyl group comprises the following steps:
[0098] The drug particles modified with carboxyl groups on the surface of the coating layer are mixed with a dopamine dispersion to graft the dopamine onto the carboxyl groups and introduce oxygen to cause oxidative self-polymerization of the dopamine to form the polydopamine.
[0099] It is understandable that the oxygen introduced may be pure oxygen or a mixed gas containing oxygen, such as air. Oxygen plays a major role in initiating the reaction, and usually only a trace amount of oxygen is required, so the flow rate of the oxygen introduced is not particularly limited.
[0100] In one example, the mass concentration of dopamine in the dopamine dispersion is 0.2% to 5%. Specifically, the mass concentration of dopamine in the dopamine dispersion includes but is not limited to: 0.2%, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%.
[0101] In one example, the pH of the dopamine dispersion is 5.8 to 8.6. Specifically, the pH of the dopamine dispersion includes but is not limited to: 5.8, 6.4, 6.6, 7.2, 7.8, 8.6. Without limitation, the pH of the dopamine dispersion can be adjusted by adding a conventional acid or base.
[0102] In one example, the mixing time is 30 min to 200 min. Specifically, the mixing time includes but is not limited to: 30 min, 40 min, 50 min, 55 min, 60 min, 65 min, 70 min, 80 min, 90 min, 100 min, 150 min, 200 min.
[0103] Furthermore, after the step of grafting polydopamine on the surface of the coating layer is completed, step S3 further includes the steps of washing and drying;
[0104] In one example, the cleaning method is water washing. Without limitation, the water washing time can be 5 minutes to 30 minutes. Specifically, the water washing time includes but is not limited to: 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, and 30 minutes.
[0105] In one example, the drying method is freeze drying.
[0106] Further optionally, the freeze-drying temperature is -60°C to -80°C, and the freeze-drying time is 6h to 10h. Specifically, the freeze-drying temperature includes but is not limited to: -60°C, -65°C, -70°C, -75°C, -80°C; the freeze-drying time includes but is not limited to: 6h, 7h, 7.5h, 8h, 9h, 10h.
[0107] The present application also provides an inner ear drug delivery preparation, comprising the polydopamine / copolymer composite microspheres as described above or the polydopamine / copolymer composite microspheres prepared by the preparation method as described above.
[0108] The present application also provides the use of the polydopamine / copolymer composite microspheres as described above or the polydopamine / copolymer composite microspheres prepared by the preparation method as described above in the preparation of drugs for treating inner ear diseases.
[0109] The following are specific examples. Unless otherwise specified, the raw materials used in the examples are all commercially available products.
[0110] The meanings of the abbreviations involved in the embodiments are as follows:
[0111] DLA: racemic lactic acid;
[0112] GA: glycolic acid;
[0113] PDLG: racemic poly(lactic-co-glycolic acid).
[0114] Example 1
[0115] This embodiment is a polydopamine / copolymer composite microsphere, and the preparation method is as follows:
[0116] (1) adding dexamethasone to water, stirring at a stirring speed of 500 rpm for 4 hours to obtain a drug aqueous solution with a mass concentration of 2%;
[0117] (2) adding PDLG having an intrinsic viscosity of 0.4-0.6 dL / g and a molar ratio of DLA to GA of 60%:40% to dichloromethane, stirring for 4 hours at a stirring speed of 800 rpm to obtain a PDLG organic phase having a mass concentration of 10%;
[0118] (3) adding the drug aqueous solution of step (1) to the PDLG organic solution of step (2) at a rate of 5 mL / min, so that the mass ratio of PDLG to dexamethasone is 80:1, and stirring at a rate of 1300 rpm for 6 hours to obtain PDLG-coated drug-loaded microspheres; centrifuging the drug-loaded microsphere solution at a speed of 6000 rpm and freeze-drying at a temperature of -70 degrees Celsius for 8 hours;
[0119] (4) immersing the drug-loaded microspheres prepared in step (3) in a sodium hydroxide aqueous solution having a mass concentration of 0.3 g / L for 60 min, so that the sodium hydroxide aqueous solution corrodes the surface of the drug-loaded microspheres, thereby introducing carboxyl groups on the surface of the drug-loaded microspheres;
[0120] (5) adding the carboxylated drug-loaded microspheres of step (4) to a 2% dopamine aqueous solution and mixing, wherein the pH value of the dopamine aqueous solution is 7.8, and at the same time, introducing oxygen into the solution to cause dopamine to oxidatively polymerize at the active sites of the drug-loaded microspheres to generate polydopamine, the reaction time is 60 min, and the mass ratio of PDLG to polydopamine is 120:1;
[0121] (6) The drug-loaded microspheres containing polydopamine on the surface obtained in step (5) were washed with deionized water for 20 minutes and freeze-dried at -70 degrees Celsius for 7 hours to prepare polydopamine / copolymer composite microspheres.
[0122] The infrared spectrum of the polydopamine / copolymer composite microspheres prepared in Example 1 is as follows: Figure 2 As shown, among them, 1736cm -1 The absorption peak of ester group is at 1150cm, which is the characteristic peak of polyester material such as polylactic acid-glycolic acid copolymer; -1 The peak is the stretching vibration peak of the ester bond; 2961cm -1The peak of the methine stretching vibration is at 1418cm -1 It is the stretching vibration peak of carbon-carbon bond.
[0123] The scanning electron microscopy image of the polydopamine / copolymer composite microspheres prepared in Example 1 is as follows: Figure 3 As shown in the picture, it can be observed that the microspheres are spherical and the particle size is about 760.57 microns.
[0124] The preparation steps of Examples 2 to 11 are the same as those of Example 1, and the main differences are the type of drug, the molar ratio of DLA and GA, the intrinsic viscosity of PDLG or the addition rate of the drug aqueous solution, as shown in Table 1.
[0125] Table 1
[0126]
[0127]
[0128] The polydopamine / copolymer composite microspheres prepared in Examples 1 to 11 were tested, and the test methods of each test are as follows:
[0129] (1) Particle size: The microspheres were observed under a microscope at 40 times magnification and a scanning electron microscope;
[0130] (2) Adhesion: In animal experiments, the adhesion of microspheres was observed by endoscopy 2 days after implantation of microspheres in the round window niche of animals. If almost no microspheres fell off, the adhesion was judged as "good", if about 50% of the microspheres fell off, it was judged as "fair", and if almost all of the microspheres fell off, it was judged as "poor".
[0131] (3) Drug release performance: The in vitro sustained release test was carried out with reference to the high performance liquid chromatography method in Part 4, 0512 of the 2020 edition of the Chinese Pharmacopoeia to determine the drug release rate of the prepared microspheres;
[0132] (4) Drug loading: Determine the drug content in the prepared microspheres by high performance liquid chromatography according to Part 4 0512 of the Chinese Pharmacopoeia 2020;
[0133] (5) Degradability: Tested with reference to YY / T 0473-2004 “In vitro degradation test of polylactide copolymers and blends for surgical implants” and YY / T 0474-2004 “In vitro degradation test of poly-L-lactide resin and its products for surgical implants”;
[0134] (6) Biocompatibility: The test was conducted in accordance with GB / T 16886.5-2017 “Biological Evaluation of Medical Devices Part 5: In vitro Cytotoxicity Test”. If the cell survival rate of the 100% concentration test sample extract was ≥70% compared with the blank control, the biocompatibility of the microspheres was judged to be “good”; if the cell survival rate was ≤70%, it was judged to be “poor”.
[0135] The test results are shown in Table 2 below.
[0136] Table 2
[0137]
[0138]
[0139] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0140] The above-described embodiments only express several implementation methods of the present application, which is convenient for understanding the technical solution of the present application in detail, but it cannot be understood as limiting the scope of protection of the patent application. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present application, several modifications and improvements can be made, which all belong to the scope of protection of the present application. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent of this application shall be based on the contents of the attached claims, and the description and drawings may be used to interpret the contents of the claims.
Claims
1. A polydopamine / copolymer composite microsphere, characterized in that: include: Drug particles, a coating layer coated on the surface of the drug particles, and polydopamine grafted on the surface of the coating layer; The coating layer is composed of racemic polylactic acid-glycolic acid copolymer.
2. The polydopamine / copolymer composite microspheres according to claim 1, characterized in that: The surface of the coating layer is modified with carboxyl groups, and the polydopamine is grafted onto the coating layer via the carboxyl groups.
3. The polydopamine / copolymer composite microspheres according to claim 1 or 2, characterized in that: The racemic poly(lactic acid-glycolic acid) copolymer has one or both of the following characteristics (1) to (2): (1) The intrinsic viscosity of the racemic poly(lactic acid-co-glycolic acid) copolymer is 0.16 dL / g to 1.2 dL / g; (2) The molar percentage of polylactic acid to glycolic acid in the racemic polylactic acid-glycolic acid copolymer is (80% to 50%): (20% to 50%).
4. The polydopamine / copolymer composite microspheres according to claim 1 or 2, characterized in that: The polydopamine / copolymer composite microspheres have one or more of the following characteristics (1) to (3): (1) The mass ratio of the racemic poly(lactic acid-glycolic acid) copolymer to the drug particles is (50-100):1; (2) The mass ratio of the racemic polylactic acid-glycolic acid copolymer to the polydopamine is (100-150):1; (3) the drug particles include a drug; Optionally, the drug includes one or more of hydrocortisone, cortisone, prednisone, methylprednisolone, prednisolone, dexamethasone, betamethasone and mometasone furoate.
5. A method for preparing polydopamine / copolymer composite microspheres, characterized in that: The steps include: preparing respectively an aqueous dispersion of the drug and an organic solvent dispersion of a racemic polylactic acid-glycolic acid copolymer; Adding the aqueous dispersion of the drug to the stirred organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer, centrifuging and drying to prepare drug particles with a coating layer on the surface; Polydopamine is grafted on the surface of the coating layer.
6. The method for preparing polydopamine / copolymer composite microspheres according to claim 5, characterized in that: Grafting polydopamine on the surface of the coating layer comprises the following steps: The surface of the coating layer is modified with carboxyl groups, and polydopamine is grafted onto the carboxyl groups.
7. The method for preparing polydopamine / copolymer composite microspheres according to claim 6, characterized in that: The polydopamine grafted on the surface of the coating layer has one or both of the following characteristics (1) to (2): (1) Modifying the surface of the coating layer with carboxyl groups comprises the following steps: Etching the surface of the coating layer to form the carboxyl group; Optionally, the etching treatment includes one or more of alkali treatment, acid treatment and plasma treatment; Further optionally, the etching treatment is an alkali treatment, and the alkali used in the alkali treatment includes one or more of sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium hydroxide, potassium carbonate and potassium bicarbonate; (2) grafting polydopamine onto the carboxyl group comprises the following steps: The drug particles after the surface of the coating layer is modified with carboxyl groups are mixed with a dopamine dispersion to graft the dopamine to the carboxyl groups and introduce oxygen to cause the dopamine to undergo oxidative self-polymerization to form the polydopamine; Optionally, the mass concentration of dopamine in the dopamine dispersion is 0.2% to 5%; Optionally, the pH of the dopamine dispersion is 5.8 to 8.6; Optionally, the oxygen is introduced for 30 min to 200 min.
8. The method for preparing polydopamine / copolymer composite microspheres according to any one of claims 5 to 7, characterized in that:The aqueous dispersion of the drug is added to the stirred organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer, and the steps of centrifugation and drying have one or more of the following characteristics (1) to (5): (1) The stirring rate is 1000 rpm to 2000 rpm; (2) The stirring time is 5h to 7h; (3) The rate of addition of the aqueous dispersion of the drug is 3 to 7 mL / min; (4) The centrifugal speed is 5000 rpm to 9000 rpm; (5) The drying method is freeze drying; optionally, the freeze drying temperature is -60°C to -80°C, and the freeze drying time is 6h to 10h.
9. The method for preparing polydopamine / copolymer composite microspheres according to any one of claims 5 to 7, characterized in that: The mass concentration of the drug in the aqueous dispersion of the drug is 0.1% to 5%.
10. The method for preparing polydopamine / copolymer composite microspheres according to any one of claims 5 to 7, characterized in that: The organic solvent dispersion of the racemic poly(lactic acid-co-glycolic acid) copolymer has one or both of the following characteristics (1) to (2): (1) The mass concentration of the racemic polylactic acid-glycolic acid copolymer in the organic solvent dispersion of the racemic polylactic acid-glycolic acid copolymer is 5% to 20%; (2) The organic solvent includes one or more of acetone, dichloromethane, chloroform, trifluoroacetic acid and hexafluoroisopropanol.
11. The method for preparing polydopamine / copolymer composite microspheres according to any one of claims 5 to 7, characterized in that: After the step of grafting polydopamine on the surface of the coating layer is completed, the steps of washing and drying are also included; Optionally, the cleaning method is water washing; Optionally, the drying method is freeze drying; Further optionally, the freeze-drying temperature is -60°C to -80°C, and the freeze-drying time is 6h to 10h.
12. An inner ear drug delivery preparation, characterized in that: The invention comprises the polydopamine / copolymer composite microspheres as claimed in any one of claims 1 to 4 or the polydopamine / copolymer composite microspheres prepared by the preparation method as claimed in any one of claims 5 to 11.
13. Use of the polydopamine / copolymer composite microspheres according to any one of claims 1 to 4 or the polydopamine / copolymer composite microspheres prepared by the preparation method according to any one of claims 5 to 11 in the preparation of drugs for treating inner ear diseases.
